NR4A1 and breast carcinoma: The recent randomized clinical trials demonstrated BCS + hormone therapy without RT yields equivalent survival and acceptable local–regional outcomes in elderly women with early-stage, node-negative (T1-2N0) hormone-receptor positive (HR +) breast cancer [17, 18].